CSL (OTCMKTS:CSLLY) Shares Gap Down – Should You Sell?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped down before the market opened on Tuesday . The stock had previously closed at $31.70, but opened at $30.23. CSL shares last traded at $31.67, with a volume of 482 shares.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Canaccord Genuity Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Jefferies Financial Group cut CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Finally, Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Five investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

CSL Price Performance

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. The firm has a fifty day moving average of $24.59 and a 200-day moving average of $24.42.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.